entertainment -WSS

entertainment

author：entertainment 2025-09-06 09:10:18 - browse：52

Adam's take main illustration — Molly Ferguson/STAT

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Chemotherapy before breast cancer surgery might fuel metastasis

WSS

California wildfire smoke linked to 52,000 early deaths, study says

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Chemotherapy before breast cancer surgery might fuel metastasis

Readers discuss the intersection of pregnancy and addiction

Is it ever OK for doctors to lie to their patients?

explore

entertainment

explore

Moonlake's readout produced a cash windfall. Risks remain

The effects of a landmark ruling on DNA ownership are becoming clearer

As demand for Covid shots wanes, Moderna seeks its next success

Deliver public health messages at the right time

Hepatitis C has a cure — but many Americans still lack access to it

Pharma companies must ensure equitable access to obesity drugs

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

My daughter's legacy lives on through her writing, phage therapy

Medical leaders decry Supreme Court decision on affirmative action

Can gargling with Listerine treat gonorrhea of the mouth?

hotspot

AltruBio raises $225 million to develop ulcerative colitis drug

Coercive sterilizations revealed by STAT prompt outrage

New report analyzes digital physical therapy solutions' effectiveness

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

focus

leisure time

explore

focus